Blood-based Molecular Biomarkers for Alzheimer's Disease

Overview

Journal Mol Brain

Publisher Biomed Central

Specialties Molecular Biology
Neurology

Date 2019 Mar 30

PMID 30922367

Citations 123

Authors

Henrik Zetterberg

Samantha C Burnham

Affiliations

Soon will be listed here.

Abstract

A major barrier to the effective conduct of clinical trials of new drug candidates against Alzheimer's disease (AD) and to identifying patients for receiving future disease-modifying treatments is the limited capacity of the current health system to find and diagnose patients with early AD pathology. This may be related in part to the limited capacity of the current health systems to select those people likely to have AD pathology in order to confirm the diagnosis with available cerebrospinal fluid and imaging biomarkers at memory clinics. In the current narrative review, we summarize the literature on candidate blood tests for AD that could be implemented in primary care settings and used for the effective identification of individuals at increased risk of AD pathology, who could be referred for potential inclusion in clinical trials or future approved treatments following additional testing. We give an updated account of blood-based candidate biomarkers and biomarker panels for AD-related brain changes. Our analysis centres on biomarker candidates that have been replicated in more than one study and discusses the need of further studies to achieve the goal of a primary care-based screening algorithm for AD.

Citing Articles

Association of plasma soluble urokinase plasminogen activator receptor concentrations and migraine with aura: a REFORM study.

Tesfay B, Ashina H, Christensen R, Al-Khazali H, Karlsson W, Amin F Brain Commun. 2025; 7(1):fcae475.

PMID: 39963289 PMC: 11831075. DOI: 10.1093/braincomms/fcae475.

Predicting conversion in cognitively normal and mild cognitive impairment individuals with machine learning: Is the CSF status still relevant?.

Russo M, Nardini D, Melchiorre S, Ciprietti C, Polito G, Punzi M Alzheimers Dement. 2025; 21(2):e14398.

PMID: 39887916 PMC: 11848327. DOI: 10.1002/alz.14398.

Oral Contraceptive Use Is Associated with Significant Differences in MicroRNA Cargo of L1CAM-Associated Extracellular Vesicles.

Lapato D, Frye R, Yakovlev V, Roberson-Nay R medRxiv. 2025; .

PMID: 39867402 PMC: 11759612. DOI: 10.1101/2025.01.15.25320605.

Advances in physiological and clinical relevance of hiPSC-derived brain models for precision medicine pipelines.

Imani Farahani N, Lin L, Nazir S, Naderi A, Rokos L, McIntosh A Front Cell Neurosci. 2025; 18():1478572.

PMID: 39835290 PMC: 11743572. DOI: 10.3389/fncel.2024.1478572.

Association and multimodal model of retinal and blood-based biomarkers for detection of preclinical Alzheimer's disease.

Ravichandran S, Snyder P, Alber J, Murchison C, Chaby L, Jeromin A Alzheimers Res Ther. 2025; 17(1):19.

PMID: 39794837 PMC: 11720872. DOI: 10.1186/s13195-024-01668-5.

References

Peng M, Jia J, Qin W . Plasma gelsolin and matrix metalloproteinase 3 as potential biomarkers for Alzheimer disease. Neurosci Lett. 2015; 595:116-21. DOI: 10.1016/j.neulet.2015.04.014. View

Llano D, Devanarayan V, Simon A . Evaluation of plasma proteomic data for Alzheimer disease state classification and for the prediction of progression from mild cognitive impairment to Alzheimer disease. Alzheimer Dis Assoc Disord. 2012; 27(3):233-43. DOI: 10.1097/WAD.0b013e31826d597a. View

Guo L, Alexopoulos P, Wagenpfeil S, Kurz A, Perneczky R . Plasma proteomics for the identification of Alzheimer disease. Alzheimer Dis Assoc Disord. 2013; 27(4):337-42. PMC: 3626738. DOI: 10.1097/WAD.0b013e31827b60d2. View

Sattlecker M, Khondoker M, Proitsi P, Williams S, Soininen H, Kloszewska I . Longitudinal Protein Changes in Blood Plasma Associated with the Rate of Cognitive Decline in Alzheimer's Disease. J Alzheimers Dis. 2015; 49(4):1105-14. DOI: 10.3233/JAD-140669. View

Olazaran J, Gil-de-Gomez L, Rodriguez-Martin A, Valenti-Soler M, Frades-Payo B, Marin-Munoz J . A blood-based, 7-metabolite signature for the early diagnosis of Alzheimer's disease. J Alzheimers Dis. 2015; 45(4):1157-73. DOI: 10.3233/JAD-142925. View

OBryant S, Xiao G, Zhang F, Edwards M, German D, Yin X . Validation of a serum screen for Alzheimer's disease across assay platforms, species, and tissues. J Alzheimers Dis. 2014; 42(4):1325-35. PMC: 4400808. DOI: 10.3233/JAD-141041. View

Mapstone M, Cheema A, Fiandaca M, Zhong X, Mhyre T, MacArthur L . Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med. 2014; 20(4):415-8. PMC: 5360460. DOI: 10.1038/nm.3466. View

Britschgi M, Rufibach K, Bauer Huang S, Clark C, Kaye J, Li G . Modeling of pathological traits in Alzheimer's disease based on systemic extracellular signaling proteome. Mol Cell Proteomics. 2011; 10(10):M111.008862. PMC: 3205866. DOI: 10.1074/mcp.M111.008862. View

Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K . Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med. 2007; 13(11):1359-62. DOI: 10.1038/nm1653. View

10.

OBryant S, Xiao G, Barber R, Huebinger R, Wilhelmsen K, Edwards M . A blood-based screening tool for Alzheimer's disease that spans serum and plasma: findings from TARC and ADNI. PLoS One. 2011; 6(12):e28092. PMC: 3233542. DOI: 10.1371/journal.pone.0028092. View

11.

Lista S, Faltraco F, Prvulovic D, Hampel H . Blood and plasma-based proteomic biomarker research in Alzheimer's disease. Prog Neurobiol. 2012; 101-102:1-17. DOI: 10.1016/j.pneurobio.2012.06.007. View

12.

Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M . CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 2016; 15(7):673-684. DOI: 10.1016/S1474-4422(16)00070-3. View

13.

Laske C, Leyhe T, Stransky E, Hoffmann N, Fallgatter A, Dietzsch J . Identification of a blood-based biomarker panel for classification of Alzheimer's disease. Int J Neuropsychopharmacol. 2011; 14(9):1147-55. DOI: 10.1017/S1461145711000459. View

14.

Leidinger P, Backes C, Deutscher S, Schmitt K, Mueller S, Frese K . A blood based 12-miRNA signature of Alzheimer disease patients. Genome Biol. 2013; 14(7):R78. PMC: 4053778. DOI: 10.1186/gb-2013-14-7-r78. View

15.

Greenberg N, Grassano A, Thambisetty M, Lovestone S, Legido-Quigley C . A proposed metabolic strategy for monitoring disease progression in Alzheimer's disease. Electrophoresis. 2009; 30(7):1235-9. DOI: 10.1002/elps.200800589. View

16.

Soares H, Chen Y, Sabbagh M, Roher A, Rohrer A, Schrijvers E . Identifying early markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels. Ann N Y Acad Sci. 2009; 1180:56-67. DOI: 10.1111/j.1749-6632.2009.05066.x. View

17.

Doecke J, Laws S, Faux N, Wilson W, Burnham S, Lam C . Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol. 2012; 69(10):1318-25. PMC: 6287606. DOI: 10.1001/archneurol.2012.1282. View

18.

Thambisetty M, Simmons A, Velayudhan L, Hye A, Campbell J, Zhang Y . Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry. 2010; 67(7):739-48. PMC: 3111021. DOI: 10.1001/archgenpsychiatry.2010.78. View

19.

Weston P, Poole T, Ryan N, Nair A, Liang Y, Macpherson K . Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration. Neurology. 2017; 89(21):2167-2175. PMC: 5696646. DOI: 10.1212/WNL.0000000000004667. View

20.

Hye A, Riddoch-Contreras J, Baird A, Ashton N, Bazenet C, Leung R . Plasma proteins predict conversion to dementia from prodromal disease. Alzheimers Dement. 2014; 10(6):799-807.e2. PMC: 4240530. DOI: 10.1016/j.jalz.2014.05.1749. View